到 2028 年的基因分型市场预测——按产品和服务、技术、应用、最终用户和地区进行的全球分析

据Stratistics MRC预测，2022年全球基因分型市场规模将达到278.9亿美元，2028年将达到1014.1亿美元，复合年增长率为24.0%，预计

基因分型是一种利用个体的 DNA 序列通过生物学实验检查其基因构成变化的方法。 这种方法有助于科学家检查遗传异常，例如 DNA 的结构变异和单核甘酸多态性。 减少错误并提供有效结果的创新技术的出现，以及癌症、糖尿病和阿尔茨海默病等目标疾病患病率的上升，正在推动市场的增长。

根据世界卫生组织的数据，2020 年全球有 1910 万新癌症患者使用基因分型进行诊断。 人类乳头瘤病毒 (HPV) 和乙型肝炎病毒 (HBV)/丙型肝炎病毒 (HCV) 等致癌病毒约占全球癌症死亡人数的 20%。

市场动态：

驱动程序

DNA 测序的技术进步和成本下降

小型化、自动化、较低的总成本、操作灵活性和包含多参数检测都是由技术突破实现的。 这些极大地提高了 DNA 测序的多功能性和使用，使医生能够专注于关键选择，例如通过不同的基因分型研究选择治疗目标并确定治疗目标的优先级。 因此，毛细管电泳、微阵列、PCR 和测序等技术在临床研究和药物开发等领域的应用越来越广泛。

约束

设备成本高

进行基因分型检测所需的设备非常昂贵，引进需要大量资金。 基因分型仪器因其先进的特性和功能而价格昂贵。 製药公司和研究实验室需要大量此类系统，需要大量投资购买大量昂贵的基因分型设备。 此类仪器总拥有成本的增加是由维护成本和其他间接成本（包括样品和人工成本）驱动的。 因此，学术研究机构难以安装或扩建 NGS 技术等尖端研究设施，阻碍了市场增长。

机会

拓展应用领域

基因分型系统的应用包括药物基因组学、诊断研究、个性化医疗和法医学。 此外，该技术还适用于各种兽医要求、食品安全和质量检查以及农村和工业环境中的环境条件。 目前，由于需要更好的治疗选择和高发病率，人类诊断学和药物基因组学是具有巨大标记潜力的领域。 这些领域还需要大规模和快速的基因分型分析，为市场增长创造广阔的机会。

威胁

基因分型数据管理调查

基因分型调查提供了大量的定量和定性数据。 过去，这些数据是手动存储的，但这是一个重大挑战，因为可以在短短几个小时内创建 TB 的数据。 随着用于存储基因分型数据的数据库的发展，技术进步使得自动化数据存储成为可能。

COVID-19 的影响：

技术进步、癌症和基因异常发生率的增加，以及对精准医学研究的研究投资增加，都是导致扩张的因素。 大流行增加了对 COVID-19 基因分型试剂盒的需求，这对基因分型业务产生了积极影响。 使用 SNP 基因分型发现了 COVID-19 的基因突变。 随着政府机构以及製药和生物技术公司加速研究，预计基因分型行业将受到政府资金增加的推动，尤其是基因组研究。

预计在预测期内最大的产品和服务部门

在产品和服务领域，各种试剂的可用性，由于全球基因分型检测量的增加对试剂的需求增加，以及医院和诊断对基因分型试剂和试剂盒的需求实验室正在增加。据推测，高增长是由于部署所需的资本支出相对较低等因素造成的。

药物基因组学有望在预测期内见证最高的复合年增长率

在预测期内，药物基因组学领域预计将以最高复合年增长率增长。 药物基因组学研究基因如何影响个体的药物反应。 该领域将基因及其作用的研究与医学科学相结合，以创造根据个人基因特征提供的有效且安全的治疗方法。 未来，它有望用于创造个性化药物，以解决心血管疾病、阿尔茨海默病、癌症和哮喘等各种健康问题，从而推动市场增长。

市场份额最高的地区：

由于技术先进产品的使用增加、大型製药和生物製药公司的存在、积极的政府政策以及医疗保健基础设施的改善，北美将在预测期内占据最高的市场份额。预计将占据 此外，大公司的存在是促成该行业高市场份额的重要因素。 製药公司对基因分型产品的需求不断增长，政府投资不断增加，技术先进的基因分型产品的采用率越来越高，医疗保健支出高

复合年增长率最高的地区：

由于该地区尚未开发的巨大潜力和越来越多的临床试验，预计亚太地区在预测期内的复合年增长率最高。 由于 FDA 建议将药物基因组学研究和基因分型纳入药物发现过程以及药物开发过程中对药物基因组学的需求不断增长等因素，预计市场将得到发展。 其他因素也可能有助于这种扩张，例如该地区製药和生物製药行业的技术发展和扩张。

主要发展：

2023 年 4 月，安捷伦和 Theragen Bio 合作推进韩国癌症基因组分析的生物信息学解决方案，新合作包括安捷伦的 SureSelect 癌症 CGP 检测和 Theragen Bio 的区域分析结合软件，转变转化研究并旨在加强精准肿瘤学

2023 年 4 月，安捷伦和 PathAI 合作为生物製药研究和临床应用提供人工智能分析开发解决方案，通过将 AI 纳入 CDx 开发，安捷伦和 PathAI 将结合分析和机器学习分析构建算法集成解决方案。

2023 年 11 月，丹纳赫启动了 Beacon Initiative，这是第一个专注于基因治疗创新的合作伙伴关係。投资于产品创新以推进重点突出的外部研发战略。

这份报告提供了什么

• 区域和国家级细分市场的市场份额评估
• 向新进入者提出战略建议
• 2020、2021、2022、2025 和 2028 年的综合市场数据
• 市场趋势（驱动因素、制约因素、机会、威胁、挑战、投资机会、建议）
• 根据市场预测在关键业务领域提出战略建议
• 竞争格局映射关键共同趋势。
• 公司简介，包括详细的战略、财务状况和近期发展
• 映射最新技术进步的供应链趋势

免费定制优惠：

购买此报告的客户将获得以下免费定制选项之一：

• 公司简介
  • 其他市场参与者的综合概况（最多 3 家公司）
  • 主要参与者的 SWOT 分析（最多 3 家公司）
• 区域细分
  • 根据客户的要求对主要国家/地区的市场估计/预测/复合年增长率（注意：基于可行性检查）。
• 竞争基准
  • 根据产品组合、区域影响力和战略联盟对主要参与者进行基准测试

内容

第 1 章执行摘要

第二章前言

• 概览
• 利益相关者
• 调查范围
• 调查方法
  • 数据挖掘
  • 数据分析
  • 数据验证
  • 研究方法
• 调查来源
  • 主要研究来源
  • 二级研究来源
  • 假设

第三章市场趋势分析

• 司机
• 约束因素
• 机会
• 威胁
• 产品分析
• 技术分析
• 应用分析
• 最终用户分析
• 新兴市场
• COVID-19 的影响

第 4 章波特五力分析

• 供应商的议价能力
• 买家的议价能力
• 替代品的威胁
• 新进入者的威胁
• 竞争公司之间的敌对关係

第 5 章全球基因分型市场：按产品和服务分类

• 基因分型服务
• 生物信息学
  • 软件
  • 服务
• 设备
  • 分析仪
  • 音序器和放大器
• 试剂和试剂盒

第 6 章全球基因分型市场：按技术分类

• 顺序
  • 焦磷酸测序
  • 下一代测序
  • 桑格测序
• 微阵列
• 聚合□链反应
  • 实时荧光定量PCR
  • 数字PCR
• MALDI-TOF
• 毛细管电泳
  • 限制性片段长度多态性
  • 单链构象多态性
  • 扩增片段长度多态性
• 其他技术

第 7 章全球基因分型市场：按应用

• 诊断和个性化医疗
• 动物遗传学
• 药物基因组学
• 其他用途

第 8 章全球基因分型市场：最终用户

• 製药和生物製药公司
• 学术机构
• 研究和诊断实验室
• 其他最终用户

第 9 章。全球基因分型市场：按地区

• 北美
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 意大利
  • 法国
  • 西班牙
  • 其他欧洲
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳大利亚
  • 新西兰
  • 韩国
  • 其他亚太地区
• 南美洲
  • 阿根廷
  • 巴西
  • 智利
  • 其他南美洲
• 中东和非洲
  • 沙特阿拉伯
  • 阿拉伯联合酋长国
  • 卡塔尔
  • 南非
  • 其他中东和非洲地区

第10章主要发展

• 合同、伙伴关係、协作和合资企业
• 收购与合併
• 新产品发布
• 业务扩展
• 其他关键策略

第11章公司简介

• Illumina Inc.
• QIAGEN
• Fluidigm Corporation
• Agilent Technologies
• Danaher Corporation
• Thermo Fisher Scientific Inc.
• Eurofins Scientific Inc.
• Bio-Rad Laboratories Inc.
• GE Healthcare Inc.
• Thermo Fisher Scientific
• PerkinElmer
• Pacific Biosciences of California
• Integrated DNA Technologies
• GENEWIZ
• Biofortuna Limited
• Precision Biomarker Resources, Inc.
• TrimGen Corporation

According to Stratistics MRC, the Global Genotyping Market is accounted for $27.89 billion in 2022 and is expected to reach $101.41 billion by 2028 growing at a CAGR of 24.0% during the forecast period. Genotyping is a method that uses an individual's DNA sequence to examine genetic make-up variations using biological experiments. This method aids scientists in examining genetic anomalies such significant DNA structural variations and single nucleotide polymorphisms. The advent of innovative technologies that significantly reduce mistakes and produce effective findings, as well as the rising prevalence of target diseases including cancer, diabetes, and Alzheimer's, fuel the market's growth.

According to WHO, 19.1 million new cancer cases were diagnosed using genotyping globally in 2020. Cancer-causing viruses such as Human Papilloma Virus (HPV) and Hepatitis B Virus (HBV)/Hepatitis C Virus (HCV) are also responsible for about 20% of cancer deaths worldwide.

Market Dynamics:

Driver:

Technological advances and falling DNA sequencing costs

Miniaturisation, automation, lower overall costs, operational flexibility, and the inclusion of multi-parameter testing have all been made possible by technological breakthroughs. All of them have significantly improved the versatility and uses of DNA sequencing, freeing doctors to concentrate on important choices like selecting and prioritising therapeutic targets through diverse genotyping research. As a result, technologies like capillary electrophoresis, microarrays, PCR, sequencing, and sequencing have seen an increase in use in areas like clinical research and drug development.

Restraint:

High cost of equipment

The equipment needed to conduct genotyping testing is quite expensive, and a significant financial expenditure is needed to install it. Genotyping equipment is expensive since it has sophisticated features and capabilities. Such systems are needed by pharmaceutical corporations and research facilities in large quantities, necessitating considerable investments to buy numerous, expensive genotyping devices. The overall rise in the total cost of ownership of these instruments is brought on by maintenance costs as well as a number of other indirect costs, including sample and labour costs. As a result, academic and research institutions struggle to install and expand cutting-edge research facilities like NGS technology which are hindering the growth of the market.

Opportunity:

Expanding application fields

Applications for genotyping systems include pharmacogenomics, diagnostic research, individualised medicine, and forensics. Additionally, this technology is suitable for various veterinary requirements, testing for food safety and quality, and environmental conditions in rural and industrial settings. Currently, the demand for better treatment choices and the high frequency of disease make human diagnostics and pharmacogenomics segments that have great marker potential. These segments also require quick genotyping analysis on a wide scale creating a wide range of opportunities for the growth of the market.

Threat:

Research using genotyping data management

Genotyping investigations both quantitatively and qualitatively provide enormous amounts of data. Previously, this data was manually saved, but this posed a significant issue because up to terabytes of data may be created in only a few hours. Through the development of databases to store genotyping data, technological improvements have made it possible to automate the data storage procedure.

COVID-19 Impact:

Technology advances, an increase in the frequency of cancer and genetic abnormalities, and increased R&D investment for precision medicine research are all factors contributing to the expansion. The pandemic raised demand for COVID-19 genotyping kits, which has had a favourable effect on the genotyping business. The genetic variations of COVID-19 have been found using SNP genotyping. The genotyping industry is anticipated to be driven by an increase in government financing, particularly for genomic research, by governmental organisations and pharmaceutical and biotechnology firms to speed up research.

The product & service segment is expected to be the largest during the forecast period

The product & service segment is estimated to have a lucrative growth, due to the availability of a wide variety of reagents, the rising demand for reagents as a result of the increased volume of genotyping tests performed globally, and the relatively low capital expenditure needed to adopt reagents and kits for genotyping in hospitals and diagnostic labs are the factors contributing to the high growth.

The pharmacogenomics segment is expected to have the highest CAGR during the forecast period

The pharmacogenomics segment is anticipated to witness the highest CAGR growth during the forecast period. Pharmacogenomics is the study of how genes impact how an individual reacts to medications. This area integrates the study of genes and their roles with the science of pharmaceuticals to create effective, secure treatments that may be provided depending on a person's genetic profile. Pharmacogenomics will be utilised in the future to create custom medications to address a variety of health issues, such as cardiovascular disease, Alzheimer's disease, cancer, and asthma thus propelling the growth of the market.

Region with highest share:

North America is projected to hold the highest market share during the forecast period owing to the growing use of technologically sophisticated goods, the existence of significant pharmaceutical and biopharmaceutical businesses, pro-active government policies, and improvements in healthcare infrastructure. Another important element contributing to the high market share in this area is the existence of big companies. Growing demand from pharmaceutical companies for genotyping products, rising government investment, increasing adoption of technologically advanced genotyping products, high healthcare expenditures

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period, due to the vast untapped potential and rising number of clinical trials being carried out in this area. Growth in the market is anticipated as a result of factors such as the FDA's recommendations to incorporate pharmacogenomics research & genotyping in the drug discovery process and the expanding demand for pharmacogenomics in the drug development process. Other causes, such as technical developments and the expanding pharma and biopharma industries in the area, might also be blamed for this expansion.

Key players in the market:

Some of the key players profiled in the Genotyping Market include Illumina Inc., QIAGEN, Fluidigm Corporation, Agilent Technologies, Danaher Corporation, Thermo Fisher Scientific Inc., Eurofins Scientific Inc., Bio-Rad Laboratories Inc., GE Healthcare Inc., Thermo Fisher Scientific, PerkinElmer, Pacific Biosciences of California, Integrated DNA Technologies, GENEWIZ, Biofortuna Limited, Precision Biomarker Resources, Inc. and TrimGen Corporation

Key Developments:

In April 2023, Agilent and Theragen Bio Partner to Advance Bioinformatic Solutions for Cancer Genomic Profiling in South Korea, New collaboration combines Agilent's SureSelect Cancer CGP assay and Theragen Bio's localized analysis software to transform translational research and enhance precision oncology

In April 2023, Agilent and PathAI Partner to Deliver AI-Powered Assay Development Solutions for Biopharma Research and Clinical Applications, By incorporating AI into CDx development, the partnership enables Agilent and PathAI to build integrated solutions with assays and machine learning analysis algorithms.

In Nov 2023, Danaher launches beacon initiative and its first partnership focused on gene therapy innovation, the program invests in product innovation to advance external R&D strategies with a focus on genomic medicines, precision diagnostics, next generation biomanufacturing, human systems, and data sciences.

Product & Services Covered:

• Genotyping Services
• Bioinformatics
• Instruments
• Reagents & Kit

Technologies Covered:

• Sequencing
• Microarrays
• PCR
• MALDI-TOF
• Capillary Electrophoresis
• Other Technologies

Applications Covered:

• Diagnostic & Personalized Medicine
• Animal Genetics
• Pharmacogenomics
• Other Applications

End Users Covered:

• Pharmaceutical & Biopharmaceutical Companies
• Academic Institutes
• Research & Diagnostic Laboratories
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Technology Analysis
• 3.8 Application Analysis
• 3.9 End User Analysis
• 3.10 Emerging Markets
• 3.11 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Genotyping Market, By Product & Service

• 5.1 Introduction
• 5.2 Genotyping Services
• 5.3 Bioinformatics
  • 5.3.1 Software
  • 5.3.2 Services
• 5.4 Instruments
  • 5.4.1 Analyzers
  • 5.4.2 Sequencers & Amplifiers
• 5.5 Reagents & Kit

6 Global Genotyping Market, By Technology

• 6.1 Introduction
• 6.2 Sequencing
  • 6.2.1 Pyrosequencing
  • 6.2.2 NGS
  • 6.2.3 Sanger Sequencing
• 6.3 Microarrays
• 6.4 PCR
  • 6.4.1 Real-Time PCR
  • 6.4.2 Digital PCR
• 6.5 MALDI-TOF
• 6.6 Capillary Electrophoresis
  • 6.6.1 Restricted Fragment Length Polymorphism
  • 6.6.2 Single-stranded Conformation Polymorphism
  • 6.6.3 Amplified Fragment Length Polymorphism
• 6.7 Other Technologies

7 Global Genotyping Market, By Application

• 7.1 Introduction
• 7.2 Diagnostic & Personalized Medicine
• 7.3 Animal Genetics
• 7.4 Pharmacogenomics
• 7.5 Other Applications

8 Global Genotyping Market, By End User

• 8.1 Introduction
• 8.2 Pharmaceutical & Biopharmaceutical Companies
• 8.3 Academic Institutes
• 8.4 Research & Diagnostic Laboratories
• 8.5 Other End Users

9 Global Genotyping Market, By Geography

• 9.1 Introduction
• 9.2 North America
  • 9.2.1 US
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 Italy
  • 9.3.4 France
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 New Zealand
  • 9.4.6 South Korea
  • 9.4.7 Rest of Asia Pacific
• 9.5 South America
  • 9.5.1 Argentina
  • 9.5.2 Brazil
  • 9.5.3 Chile
  • 9.5.4 Rest of South America
• 9.6 Middle East & Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 UAE
  • 9.6.3 Qatar
  • 9.6.4 South Africa
  • 9.6.5 Rest of Middle East & Africa

10 Key Developments

• 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 10.2 Acquisitions & Mergers
• 10.3 New Product Launch
• 10.4 Expansions
• 10.5 Other Key Strategies

11 Company Profiling

• 11.1 Illumina Inc.
• 11.2 QIAGEN
• 11.3 Fluidigm Corporation
• 11.4 Agilent Technologies
• 11.5 Danaher Corporation
• 11.6 Thermo Fisher Scientific Inc.
• 11.7 Eurofins Scientific Inc.
• 11.8 Bio-Rad Laboratories Inc.
• 11.9 GE Healthcare Inc.
• 11.10 Thermo Fisher Scientific
• 11.11 PerkinElmer
• 11.12 Pacific Biosciences of California
• 11.13 Integrated DNA Technologies
• 11.14 GENEWIZ
• 11.15 Biofortuna Limited
• 11.16 Precision Biomarker Resources, Inc.
• 11.17 TrimGen Corporation

List of Tables

• Table 1 Global Genotyping Market Outlook, By Region (2020-2028) ($MN)
• Table 2 Global Genotyping Market Outlook, By Product & Service (2020-2028) ($MN)
• Table 3 Global Genotyping Market Outlook, By Genotyping Services (2020-2028) ($MN)
• Table 4 Global Genotyping Market Outlook, By Bioinformatics (2020-2028) ($MN)
• Table 5 Global Genotyping Market Outlook, By Software (2020-2028) ($MN)
• Table 6 Global Genotyping Market Outlook, By Services (2020-2028) ($MN)
• Table 7 Global Genotyping Market Outlook, By Instruments (2020-2028) ($MN)
• Table 8 Global Genotyping Market Outlook, By Analyzers (2020-2028) ($MN)
• Table 9 Global Genotyping Market Outlook, By Sequencers & Amplifiers (2020-2028) ($MN)
• Table 10 Global Genotyping Market Outlook, By Reagents & Kit (2020-2028) ($MN)
• Table 11 Global Genotyping Market Outlook, By Technology (2020-2028) ($MN)
• Table 12 Global Genotyping Market Outlook, By Sequencing (2020-2028) ($MN)
• Table 13 Global Genotyping Market Outlook, By Pyrosequencing (2020-2028) ($MN)
• Table 14 Global Genotyping Market Outlook, By NGS (2020-2028) ($MN)
• Table 15 Global Genotyping Market Outlook, By Sanger Sequencing (2020-2028) ($MN)
• Table 16 Global Genotyping Market Outlook, By Microarrays (2020-2028) ($MN)
• Table 17 Global Genotyping Market Outlook, By PCR (2020-2028) ($MN)
• Table 18 Global Genotyping Market Outlook, By Real-Time PCR (2020-2028) ($MN)
• Table 19 Global Genotyping Market Outlook, By Digital PCR (2020-2028) ($MN)
• Table 20 Global Genotyping Market Outlook, By MALDI-TOF (2020-2028) ($MN)
• Table 21 Global Genotyping Market Outlook, By Capillary Electrophoresis (2020-2028) ($MN)
• Table 22 Global Genotyping Market Outlook, By Restricted Fragment Length Polymorphism (2020-2028) ($MN)
• Table 23 Global Genotyping Market Outlook, By Single-stranded Conformation Polymorphism (2020-2028) ($MN)
• Table 24 Global Genotyping Market Outlook, By Amplified Fragment Length Polymorphism (2020-2028) ($MN)
• Table 25 Global Genotyping Market Outlook, By Other Technologies (2020-2028) ($MN)
• Table 26 Global Genotyping Market Outlook, By Application (2020-2028) ($MN)
• Table 27 Global Genotyping Market Outlook, By Diagnostic & Personalized Medicine (2020-2028) ($MN)
• Table 28 Global Genotyping Market Outlook, By Animal Genetics (2020-2028) ($MN)
• Table 29 Global Genotyping Market Outlook, By Pharmacogenomics (2020-2028) ($MN)
• Table 30 Global Genotyping Market Outlook, By Other Applications (2020-2028) ($MN)
• Table 31 Global Genotyping Market Outlook, By End User (2020-2028) ($MN)
• Table 32 Global Genotyping Market Outlook, By Pharmaceutical & Biopharmaceutical Companies (2020-2028) ($MN)
• Table 33 Global Genotyping Market Outlook, By Academic Institutes (2020-2028) ($MN)
• Table 34 Global Genotyping Market Outlook, By Research & Diagnostic Laboratories (2020-2028) ($MN)
• Table 35 Global Genotyping Market Outlook, By Other End Users (2020-2028) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.